Peripheral Blood Mononuclear Cell Populations Correlate with Outcome in Patients with Metastatic Breast Cancer.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
13 05 2022
Historique:
received: 23 03 2022
revised: 04 05 2022
accepted: 11 05 2022
entrez: 28 5 2022
pubmed: 29 5 2022
medline: 1 6 2022
Statut: epublish

Résumé

Local tumor-associated immune cells hold prognostic and predictive value in various forms of malignancy. The role of systemic, circulating leukocytes is, however, not well-characterized. In this prospective and explorative study, we aim to delineate the clinical relevance of a broad panel of circulating immune cells in 32 patients with newly diagnosed metastatic breast cancer (MBC) before the start of systemic treatment. Freshly isolated peripheral blood mononuclear cells (PBMCs) were analyzed by flow cytometry and evaluated for potential associations to clinicopathological variables and patient outcome. We show that the levels of specific circulating leukocyte populations are associated with clinical parameters such as hormone receptor status, histological subtype, number of circulating tumor cells (CTCs) and metastatic burden. Importantly, high levels of CD8

Identifiants

pubmed: 35626676
pii: cells11101639
doi: 10.3390/cells11101639
pmc: PMC9139201
pii:
doi:

Substances chimiques

Antineoplastic Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
Oncotarget. 2017 May 30;8(22):35656-35668
pubmed: 27374101
Nat Med. 2008 May;14(5):518-27
pubmed: 18438415
Cancer Immunol Immunother. 2014 Jan;63(1):45-57
pubmed: 24100804
Breast Cancer Res. 2020 Dec 23;22(1):140
pubmed: 33357231
Life Sci Alliance. 2020 Sep 21;3(11):
pubmed: 32958605
J Clin Oncol. 2011 May 20;29(15):1949-55
pubmed: 21483002
Cancers (Basel). 2021 Mar 15;13(6):
pubmed: 33804027
BMC Cancer. 2012 Jul 23;12:306
pubmed: 22824040
Nat Rev Clin Oncol. 2016 Apr;13(4):228-41
pubmed: 26667975
Pathobiology. 2020;87(2):125-142
pubmed: 32325459
Breast Cancer Res. 2018 Jun 8;20(1):48
pubmed: 29884204
Ann Oncol. 2017 Jan 1;28(1):16-33
pubmed: 28177437
Oncotarget. 2017 Mar 28;8(13):21539-21553
pubmed: 28423487
Nat Rev Dis Primers. 2019 Sep 23;5(1):66
pubmed: 31548545
J Cancer. 2016 Jun 03;7(9):1095-104
pubmed: 27326253
Clin Breast Cancer. 2019 Dec;19(6):433-442
pubmed: 31383605
Cancer Immunol Res. 2019 Aug;7(8):1280-1292
pubmed: 31189644
JAMA Oncol. 2017 Apr 01;3(4):524-548
pubmed: 27918777
Ther Adv Med Oncol. 2019 Aug 14;11:1758835919866065
pubmed: 31452692
Lancet. 2020 Dec 5;396(10265):1817-1828
pubmed: 33278935
PLoS One. 2015 May 20;10(5):e0127028
pubmed: 25992611
Cancer Immunol Immunother. 2020 Mar;69(3):435-448
pubmed: 31925475
Cytometry B Clin Cytom. 2012 Jan;82(1):54-8
pubmed: 21936048
J Immunother Cancer. 2016 Oct 18;4:59
pubmed: 27777769
J Immunother Cancer. 2021 Mar;9(3):
pubmed: 33757987
Cancer Discov. 2011 Jun;1(1):54-67
pubmed: 22039576
PLoS One. 2016 Apr 13;11(4):e0152500
pubmed: 27073890
Cancer Res. 1996 Oct 15;56(20):4625-9
pubmed: 8840975
Cancer Lett. 2017 May 1;393:1-7
pubmed: 28216374
Breast. 2017 Oct;35:142-150
pubmed: 28735162
Sci Rep. 2019 Sep 17;9(1):13451
pubmed: 31530882
BMC Cancer. 2016 Aug 26;16:687
pubmed: 27566250
Front Immunol. 2018 May 30;9:1209
pubmed: 29899747
Ann Oncol. 2020 Dec;31(12):1623-1649
pubmed: 32979513
Pathobiology. 2020;87(2):61-74
pubmed: 31715606
J Transl Med. 2016 Jan 06;14:2
pubmed: 26733325
Clin Exp Immunol. 2011 Apr;164(1):57-65
pubmed: 21361908
J Transl Med. 2015 Jun 04;13:180
pubmed: 26040463
Breast Cancer Res. 2014 Sep 06;16(5):432
pubmed: 25193543
Immunology. 2018 May;154(1):3-20
pubmed: 29313948
Breast Cancer Res. 2012 Mar 15;14(2):R48
pubmed: 22420471
Biomed Rep. 2016 Aug;5(2):208-212
pubmed: 27446543
Cancer Med. 2019 Feb;8(2):492-500
pubmed: 30632318
Cancer Immunol Immunother. 2019 Oct;68(10):1671-1680
pubmed: 30905043

Auteurs

Anna-Maria Larsson (AM)

Division of Oncology, Department of Clinical Sciences Lund, Lund University, SE-223 81 Lund, Sweden.

Olle Nordström (O)

Experimental Infection Medicine, Department of Translational Medicine, Lund University, SE-214 28 Malmö, Sweden.

Alexandra Johansson (A)

Division of Oncology, Department of Clinical Sciences Lund, Lund University, SE-223 81 Lund, Sweden.

Lisa Rydén (L)

Division of Oncology, Department of Clinical Sciences Lund, Lund University, SE-223 81 Lund, Sweden.
Department of Surgery, Skåne University Hospital, SE-223 81 Lund, Sweden.

Karin Leandersson (K)

Cancer Immunology, Department of Translational Medicine, Lund University, SE-214 28 Malmö, Sweden.

Caroline Bergenfelz (C)

Experimental Infection Medicine, Department of Translational Medicine, Lund University, SE-214 28 Malmö, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH